ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection
Open Access
- 6 October 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139317
Abstract
Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. The aim of the present study was to investigate the association between the functional ITPA variants and hematological side effects during antiviral therapy with pegylated interferon (PegIFN) and RBV. This cohort study included all consecutive Caucasian patients treated for chronic HCV infection with PegIFN and RBV between 2000 and 2009 for whom a serum sample was available for genetic testing. The predicted inosine triphosphate pyrophosphatase (ITPase) activity was based on the genotypes of the SNPs rs1127354 and rs7270101. Decline in hemoglobin (Hb) during antiviral therapy, as well as dose reductions, blood transfusions and use of erythropoietin were assessed. In total, 213 patients were included. The predicted ITPase activity was normal among 152 (71%) patients; 61 (29%) patients had ITPase deficiency. By multivariable linear regression, RBV dose in mg per kilogram (Beta 0.09, 95%CI 0.04–0.13, pITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection. Patients with normal ITPase activity underwent more dose reductions of RBV and received erythropoietin more frequently.Keywords
This publication has 37 references indexed in Scilit:
- Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevirJournal of Viral Hepatitis, 2013
- Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsJournal of Hepatology, 2011
- Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRHepatology, 2010
- Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevirHepatology, 2010
- Risk Factors for Infection During Treatment with Peginterferon alfa and Ribavirin for Chronic Hepatitis CHepatology, 2010
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization StudiesAmerican Journal of Epidemiology, 2009
- Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis CGastroenterology, 2007
- Genetic basis of inosine triphosphate pyrophosphohydrolase deficiencyHuman Genetics, 2002
- Differential Effect of Erythropoietin and GM‐CSF on Megakaryocytopoiesis from Primitive Bone Marrow Cells in Serum‐Free ConditionsStem Cells, 1997